Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 2 of 3 for:    ck-2127107

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Astellas Pharma Inc
Sponsor:
Collaborator:
Cytokinetics
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
ClinicalTrials.gov Identifier:
NCT02662582
First received: January 20, 2016
Last updated: February 23, 2017
Last verified: February 2017
  Purpose

The purpose of this study is to assess the effect of CK-2127107 relative to placebo on cycle ergometer exercise tolerance, assessed as change from period baseline in constant work rate (CWR) endurance time, utilizing a breath-by-breath metabolic measurement system with integrated electrocardiogram (ECG). The time to intolerance is assessed by a stopwatch and verified from electronic recordings of the cycle ergometer.

This study will also assess cardiopulmonary and neuromuscular effects of CK-2127107 relative to placebo; the effect of CK-2127107 on resting spirometry relative to placebo; the safety and tolerability of CK-2127107 as well as the pharmacokinetics of CK-2127107.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: CK-2127107
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Two Period, Crossover Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Change from period baseline in Constant Work Rate (CWR) endurance time [ Time Frame: Baseline and up to Day 14 of each treatment period ]

Secondary Outcome Measures:
  • Change from period baseline in oxygen uptake (VO2) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in ventilation (VE) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in ventilatory equivalent for carbon dioxide (VE/VCO2) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in inspiratory capacity (IC) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in fractions of expired O2 (FeO2 ) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in fractions of expired CO2 (FeCO2) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in minute ventilation [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in oxygen consumption (VO2) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in carbon dioxide production (VCO2) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline respiratory exchange ratio (RER) [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change from period baseline in perceived exertion for dyspnea and leg discomfort (Borg CR10) at isotime during CWR [ Time Frame: Baseline and up to Day 14 of each treatment period ]
    The Borg Scale (Borg CR10) is a simple 10-item method of rating perceived exertion (RPE) and collects information on perceived exertion in an individual's rating of exercise intensity. Subjects will be asked to use this scale to rate the intensity of their breathing and leg discomfort before, during, and after exercise. Scores range from 0 (Complete Rest) to 10 (Extremely Hard (almost maximal)).

  • Change from period baseline in activation of accessory respiratory muscles (by electromyogram) at isotime and peak exercise during CWR [ Time Frame: Baseline and up to Day 14 of each treatment period ]
  • Change in resting spirometry [ Time Frame: Baseline and up to Day 14 of each treatment period ]

Estimated Enrollment: 40
Study Start Date: June 2016
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CK-2127107, then Placebo
Participants will first receive CK-2127107 for 14 days. After a washout period of 14 days, participants will then receive matching Placebo for 14 days.
Drug: CK-2127107
Oral
Drug: Placebo
Oral
Experimental: Placebo, then CK-212710
Participants will first receive Placebo for 14 days. After a washout period of 14 days, participants will then receive matching CK-2127107 for 14 days.
Drug: CK-2127107
Oral
Drug: Placebo
Oral

Detailed Description:
Enrolled participants will be randomly assigned to 1 of 2 treatment sequences and will receive both CK-2127107 and matching placebo over 2 treatment periods.
  Eligibility

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has a body mass index (BMI) of 18-35 kg/m2 inclusive.
  • Subject must have all of the following:

    • Clinical diagnosis of moderate to severe COPD, with a postbronchodilator FEV1/FVC ratio < 70% and 30% ≤ FEV1 < 65% predicted at screening. The predicted values for normal spirometry will be those recommended by the American Thoracic Society (ATS) / European Respiratory Society (ERS) [Miller et al, 2005].
    • General stable health with no change in medication (including non-COPD agents and dietary aids/food supplements) within 2 weeks prior to screening, no systemic corticosteroid administration (topical or inhaled corticosteroids are allowed) within 6 weeks prior to screening, no exacerbations or hospitalization within 6 weeks prior to screening.
    • Current or ex-smokers with a smoking history of at least 10 pack years.
    • Grade of 2 or 3 on the Modified Medical Research Council (mMRC) Dyspnea Scale at screening:

      1. Grade 2: walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level.
      2. Grade 3: stops for breath after walking about 100 meters or after a few minutes on the level.
  • Subject is able to complete technically acceptable respiratory muscle strength tests, spirometry, muscle strength test, physical performance test and exercise tests.
  • Subject is willing to wear an accelerometer during waking hours in assigned periods during the study.
  • Female subject must either:

    • Be of non-child bearing potential: Postmenopausal (defined as at least 1 year without any menses) prior to screening, or documented surgically sterile.
    • Or, if of childbearing potential: Agree not to try to become pregnant during the study and for 28 days after the last dose, and have a negative serum pregnancy test at screening, and, if heterosexually active, agree to consistently use 2 forms of highly-effective birth control (at least 1 of which must be a barrier method) starting at screening, throughout the study, and for 28 days after the last dose.
  • Female subject must agree not to breastfeed starting at screening and throughout the study and for 28 days after the last dose.
  • Female subject must not donate ova starting at screening, throughout the study and for 28 days after the last dose.
  • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective form of contraception consisting of 2 forms of birth control (at least 1 of which must be a barrier method) starting at screening, and continuing throughout the study and for 90 days after the last dose.
  • Male subject must not donate sperm starting at screening, throughout the study and for 90 days after the last dose.
  • Subject agrees not to participate in another interventional study from screening through the follow-up visit (FUV) of the study.

Exclusion Criteria:

  • Subject has previously enrolled in a clinical study of CK-2127107.
  • Subject has any clinically significant abnormality following the investigator's review of the physical examination, ECG and protocol-defined clinical laboratory tests at screening. A significant abnormality is defined as an abnormality which, in the opinion of the investigator, may (i) put the subject at risk because of participation in the study, (ii) influence the results of the study or (iii) cause concern regarding the subject's ability to participate in the study.
  • Subject has any of the liver function tests (LFTs; i.e., aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], γ-glutamyl transferase [GGT] and/or total bilirubin [TBL]) above 1.5 times the upper limit of normal (ULN) at screening. These assessments may be repeated once at the investigator's discretion (within the screening window).
  • Subject has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2 by the Cockcroft-Gault equation at screening.
  • Subject has a serious cardiovascular disease, including a current New York Heart Association (NYHA) class III or IV congestive heart failure or clinically significant valvular disease, history of cardiac arrest, uncontrolled angina or arrhythmia, untreated serious conduction disorder (e.g., third-degree heart block), or acute myocardial ischemic condition suspected on the ECG at screening (e.g., ST-segment elevation, ST-segment depressions > 2 mm).
  • Subject has had a myocardial infarction or other acute coronary syndrome, major heart surgery (i.e., valve replacement or bypass surgery), stroke, deep vein thrombosis or pulmonary embolus in the 6 months prior to screening.
  • Subject has known active tuberculosis.
  • Subject has undergone thoracotomy with pulmonary resection (except for sub-lobar resection).
  • Subject has resting pulse < 40 bpm or > 100 bpm; resting systolic blood pressure > 160 mm Hg or < 90 mm Hg; resting diastolic blood pressure > 100 mm Hg at screening. These assessments may be repeated once at the investigator's discretion (within the screening window).
  • Subject desaturates to SpO2 < 85% for at least 1 minute on screening IET.
  • Subject has a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnea/shortness of breath (considered to be due to COPD), such as arthritis in the leg, angina pectoris, heart failure, claudication or morbid obesity.
  • Subject has a CWR cycle ergometry endurance time less than 4 or greater than 8 minutes after WR adjustment procedures.
  • Subject has used the following drugs within 14 days prior to day -1:

    • Strong cytochrome P450 (CYP)3A4 inhibitor (e.g., itraconazole, clarithromycin).
    • Strong CYP3A4 inducer (e.g., barbiturates, rifampin).
  • Subject has hemoglobin (Hb) concentration below 10.0 g/dL at screening.
  • Subject has a cancer requiring treatment currently or in the past 3 years (except primary nonmelanoma skin cancer, carcinoma in situ or cancers that have an excellent prognosis such as early stage breast or prostate cancer).
  • Subject giving a history of asthma, allergic rhinitis or atopy shall be evaluated by the investigator to determine whether the subject's predominant diagnosis is COPD rather than asthma.
  • Subject has neurological conditions or neuromuscular diseases that are causing impaired muscle function or mobility.
  • Subject has a current diagnosis of schizophrenia, other psychotic disorders or bipolar disorder.
  • Subject in the active phase of pulmonary rehabilitation or had completed pulmonary rehabilitation or exercise training within the 13 weeks prior to screening.
  • Subject has severe and/or uncontrolled medical conditions that could interfere with the study (e.g., severe neurological deficit after stroke, developed diabetic peripheral neuropathy, respiratory diseases requiring daytime supplemental oxygen, infection, gastrointestinal disorder, uncontrolled pain or any other non-stable illness) as judged by the medical investigator.
  • Subject has a known history of positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody or history of a positive test for human immunodeficiency virus (HIV) infection.
  • Subject has a history of alcoholism or drug/chemical substance abuse within 2 years prior to screening.
  • Subject has used any medications known to affect physical function or muscle mass including androgen supplements, anti-androgens (such as luteinizing hormone-releasing hormone [LHRH] agonists), anti-estrogen (tamoxifen, etc.), recombinant human growth hormone (rhGH), insulin, oral beta adrenergic agonists, megestrol acetate, dronabinol, metformin or other drugs which, in the opinion of the investigator, might influence physical function or muscle mass within 6 weeks prior to screening.
  • Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 28 days or 5 half-lives whichever is longer, prior to the initiation of screening.
  • Subject has any other condition that in the opinion of the investigator precludes the subject's participation in the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02662582

Contacts
Contact: Astellas Pharma Global Development 800-888-7704 ext 5473 astellas.registration@astellas.com

Locations
United States, California
Site US10001 Recruiting
Torrance, California, United States, 90502
United States, Pennsylvania
Site US10003 Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Cytokinetics
Investigators
Study Director: Senior Medical Director Astellas Pharma Global Development, Inc.
  More Information

Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT02662582     History of Changes
Other Study ID Numbers: 3318-CL-3002
Study First Received: January 20, 2016
Last Updated: February 23, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Astellas Pharma Inc:
Chronic Obstructive Pulmonary Disease
CK-2127107
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 27, 2017